News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oxagen Limited Announces Completion of Recruitment in Phase IIb Dose Range-Finding Clinical Trial in New Oral Treatment for Asthma



12/9/2009 9:42:26 AM

Bookmark and Share

ABINGDON, UK--(BUSINESS WIRE)--Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES